L-4F treatment increases circulating adiponectin in vivo and increases adiponectin expression by BMSCs. (A) Expression of HMW adiponectin, as measured by Western blot, in mice treated with L-4F for 21 days, compared with baseline. A representative Western blot image is shown. Data are mean ± SEM of 5 mice. *P < .05. (B) Quantitative real-time PCR measurement of adiponectin/GAPDH ratios in ST2 and KaLwRij BMSCs after treatment with L-4F for 48 hours. **P < .01 and ***P < .005, compared with control. (C) Myeloma cell proliferation, as measured by MTS assay, after treatment with 10 to 40 μg/mL L-4F for 24 to 72 hours. (D) Myeloma cells were treated with 20% conditioned media from KaLwRij or adiponectin knockout BMSCs that had been treated with 40 μg/mL L-4F or vehicle control. Apoptotic and viable cells were quantitated by annexin V/propidium iodide staining and flow cytometric analysis. *P < .05, compared with KaLwRij vehicle control. Data are mean ± SEM.